Margaret Wood Hassan

Senators Hassan, Budd Introduce Bipartisan Bill to... | U.S. Senator Maggie Hassan of New Hampshire

Position: Senators Hassan and Budd support legislation requiring the FDA to publicly determine and disclose when brand-name biologic drug exclusivity periods end, enabling lower-cost generic alternatives to reach the market more quickly and increase competition.

WASHINGTON – U.S. Senators Maggie Hassan (D-NH) and Ted Budd (R-NC) introduced bipartisan legislation that would expedite the development of “generic” biologic medications. The Medication Competition Act would require the FDA to publicly determine and then list when brand-name drug exclusivity ends, allowing lower-cost alternatives to come to market more quickly. Biologic drugs are a complex kind of medication commonly used in cancer immunotherapy, autoimmune condition treatment, and certain insulin products. Biologic drugs tend to cost more than other medications, and very few biologic drugs have generic alternatives. “Big Pharma benefits from a loophole in federal law where it can keep the exclusivity dates on certain prescription drugs secret, making it harder for competitors to enter the market,” said Senator Hassan. “This bipartisan bill requires the FDA to publicly determine and disclose when these exclusivity periods end, helping bring lower-cost alternatives to the market sooner. I urge my colleagues to support this commonsense effort to bring more transparency and competition to the market.” “To lower the cost of prescription drugs, we need to enable low-cost biological drugs to reach consumers faster. Unclear policy on the exclusivity periods of biologics at the FDA is inhibiting competition, making it more challenging for the manufacturers of these lower-cost alternatives to develop new medicines. I am glad to join Senator Hassan in closing this loophole to help patients access the drugs they need at more affordable prices,” said Senator Budd. Federal law requires the FDA to publicly specify the exclusivity period for biologic medications when the agency already knows it. However, a loophole in the law does not require FDA to actually calculate the exclusivity period for all biologic drugs, meaning that of the more than 200 currently approved drugs in this category, only three currently have the exclusivity period publicly listed. Closing this loophole is critical to helping generic drug manufacturers plan for new lower-priced products — increasing competition, lowering costs for families, and stopping Big Pharma monopolies from going on longer than necessary. This legislation is part of Senator Hassan’s work to lower prescription drug costs for Americans. Earlier this year, two of Senator Hassan’s bipartisan measures to lower prescription drug costs passed into law. The Increasing Transparency in Generic Drug Applications Act will speed the approval of generic drugs by ending the lengthy guessing game that manufacturers currently go through with the FDA, enabling generic drugs to get to market sooner, lowering prices for consumers, and saving taxpayer dollars. The Patients Before Middlemen (PBM) Act helps stop pharmacy benefit managers from driving up prescription drug pricing for seniors. Last month, Senator Hassan successfully forced a big pharmaceutical company to abandon its monopoly and egregious price hike strategy to allow a lower-cost generic inhaler for children to enter the market.

Senator Hassan Presses For-Profit Methadone Clinic... | U.S. Senator Maggie Hassan of New Hampshire

Position: Senator Hassan is investigating for-profit methadone clinics for allegedly creating barriers to medication-assisted treatment access and is pressing for expanded access to methadone and buprenorphine as evidence-based opioid addiction treatment.

WASHINGTON – U.S. Senator Maggie Hassan (D-NH), Ranking Member of the Senate Finance Subcommittee on Health Care, today pressed New Season – the largest operator of methadone clinics in New Hampshire – for answers amid an ongoing investigation led by the Senator. Her request makes public for the first time serious allegations against New Season of actions that make it harder for people to receive the addiction treatment they need. This request is part of Senator Hassan’s overall efforts to expand access to medication-assisted treatment, which includes methadone and buprenorphine. Medication-assisted treatment is considered the gold standard for opioid addiction treatment, as it helps people recover and significantly decreases the likelihood of relapse. “Drug overdoses killed nearly 79,400 Americans in 2024 — and nearly 300 New Hampshire residents — yet only 25 percent of Americans with opioid addiction receive medication-assisted treatment, the gold standard for opioid addiction treatment,” wrote Senator Hassan as part of her push for answers from New Season. “These allegations are described below and, if true, require prompt corrective action.” Senator Hassan’s ongoing investigation into barriers to care at for-profit methadone clinics in New Hampshire has thus far uncovered allegations by current employees, former employees, and patients of New Season, including: Click here to read Senator Hassan’s letter to New Season. Senator Hassan’s request issued today is the latest step in the overall investigation she launched in August 2025 into whether patients at for-profit methadone clinics – including New Season – encounter unnecessary barriers when seeking lifesaving methadone treatment for opioid addiction. In December, as part of this investigation, Senator Hassan launched a community survey learn about the experiences that Granite Staters have had with methadone clinics in New Hampshire. Senator Hassan continues to work to combat the fentanyl crisis and expand access to evidence-based addiction treatment. Senator Hassan helped introduce the Modernizing Opioid Treatment Access Act, bipartisan legislation to improve access to medication-assisted treatment by allowing more addiction specialists to prescribe methadone. In 2022, Senator Hassan successfully passed into law her bipartisan Mainstreaming Addiction Treatment (MAT) Act to increase the number of medical professionals authorized to prescribe medication-assisted treatment.

In Exeter, Senator Hassan Hears from Small Manufac... | U.S. Senator Maggie Hassan of New Hampshire

Position: Senator Hassan opposes President Trump's tariffs, arguing they harm small manufacturers by raising input costs, reducing profit margins, and contributing to manufacturing job losses. She calls for the President to reverse course and work with Congress on a bipartisan basis to support small manufacturers.

Visit Follows Release of New Report Detailing Harmful Impact of Tariffs and Uncertainty on Small Manufacturers EXETER – U.S. Senator Maggie Hassan yesterday visited Mace Machine, a small manufacturer in Exeter, to hear about the ways in which President Trump’s tariffs are hurting their business. During her visit to the manufacturer – which makes specialized parts and components used in electronics, aerospace, and national defense products – Senator Hassan spoke with Mace Machine’s leaders about the impact of the rising costs of inputs that the company has faced since President Trump imposed his tariffs last year. “Small businesses like Mace Machine are at the core of American manufacturing,” said Senator Hassan. “But, as I heard yesterday, President Trump’s reckless tariffs have created unnecessary burdens for small manufacturers by hiking costs for the inputs that they rely on. The President needs to reverse course and work with Congress on a bipartisan basis to support small manufacturers like Mace Machine who power our economy and strengthen our national security.” Last week, the Joint Economic Committee – Minority, which Senator Hassan leads as Ranking Member, issued a new report that details the ways in which President Trump’s reckless tariffs have inflicted harm on the small businesses that make up the American manufacturing base. In his inauguration speech, President Trump promised to make the U.S. “a manufacturing nation once again.” Yet more than a year into his second term, the Trump administration’s policies have done the opposite – resulting in a loss of more than 100,000 manufacturing jobs and a significant decline in small manufacturers’ profit margins.

Senators Hassan, Banks Press School Safety Platfor... | U.S. Senator Maggie Hassan of New Hampshire

WASHINGTON – U.S. Senators Maggie Hassan (D-NH) and Jim Banks (R-IN) pressed Navigate360, which operates a school safety platform, for answers about how it is responding to a cyberattack on its tip line. Navigate360’s P3 Global Intel tip line, which schools across the country use to facilitate reporting of safety concerns, abuse, and thoughts of self-harm, recently suffered a massive security breach. Reports suggest that the cyberattackers were able to steal and publicly release children’s highly sensitive personal information. The Senators are demanding answers about the threat to students and how the exposure of personal information could disincentivize reports about threats and other safety concerns. “Your company markets its product as an anonymous tip line,” wrote the Senators. “However, the personally identifiable information recently released by the hackers suggests otherwise. This puts the safety of students at risk and undermines public trust in using such platforms to report suspicious activity. Education and school safety experts have expressed concerns that, without guaranteed anonymity, students will choose not to report safety concerns.” The Senators pressed the company to provide answers about the attack, including what precautions it is taking to prevent future attacks: “We are particularly concerned by reports that the cyberattack exploited platform vulnerabilities in order to steal students’ highly sensitive personally identifiable information. We urge you to provide the public clarity regarding what data was stolen, how Navigate360 is responding, and what safeguards Navigate360 will put into place to prevent this from happening again.” Read the Senators’ full letter to Navigate360 here or below: Dear Mr. Guilbault, Mr. Szigethy, and Mr. Kohl: We write to express significant concern about the risks to students, staff, and schools from a recent cyberattack on your company’s P3 Global Intel tip line. We are particularly concerned by reports that the cyberattack exploited platform vulnerabilities in order to steal students’ highly sensitive personally identifiable information. We urge you to provide the public clarity regarding what data was stolen, how Navigate360 is responding, and what safeguards Navigate360 will put into place to prevent this from happening again. According to recent reports, malicious actors breached Navigate360’s P3 Global Intel platform last month, stole significant amounts of data, and have since released that data online. More than 35,000 schools and 5,000 public safety agencies use Navigate360’s products, meaning that sensitive personal data for millions of Americans may have been stolen. Schools across the country use Navigate360’s P3 Global Intel platform to allow for the safe and secure reporting of safety concerns and threats of violence to school communities. Students also use this resource to report abuse and thoughts of self-harm. Your company markets its product as an anonymous tip line. However, the personally identifiable information recently released by the hackers suggests otherwise. This puts the safety of students at risk and undermines public trust in using such platforms to report suspicious activity. Education and school safety experts have expressed concerns that, without guaranteed anonymity, students will choose not to report safety concerns. So far, your company has hired an independent third party to investigate the recent cyberattack. We urge you to be transparent with the public about the findings of this investigation, and we request your prompt and comprehensive answers to the following questions: Thank you for your attention to this important matter. We ask that you reply no later than May 8, 2026.

Senators Hassan, Grassley Call for Review of Big P... | U.S. Senator Maggie Hassan of New Hampshire

Position: Senators Hassan and Grassley call for a Government Accountability Office investigation into pharmaceutical companies' use of prescription drug coupons that lower upfront patient costs but are discontinued without notice, keeping overall drug prices high and creating unpredictable out-of-pocket expenses.

WASHINGTON – U.S. Senators Maggie Hassan (D-NH), and Chuck Grassley (R-IA) are calling on the Government Accountability Office to investigate pharmaceutical companies’ use of “coupons,” as a tactic used to steer patients away from lower-cost generics. The Senators are asking GAO to investigate the ways in which pharmaceutical companies use drug coupons to lure in patients with lower upfront costs but then discontinue those coupons with little to no notice, leaving people with higher bills at the pharmacy counter. Over time, this can keep drug prices high, create unpredictable out-of-pocket costs, and raise insurance premiums for everyone. “Drug companies are often able to keep their drug prices outrageously high by setting their own list prices, and then offering copay coupons in order to help some patients afford those high prices.” Senators Hassan and Grassley wrote. “Companies also use drug coupons to increase drug sales for a particular brand-name drug and to steer patients away from lower-cost generics. In fact, pharmaceutical companies earn as much as $4 more in drug sales for every $1 that they spend on prescription drug coupons.” “While these coupons often lower or eliminate the patient’s copays in the short-term, in the long-term they could lead to the patient unnecessarily paying more for the brand-name drug. Brand-name drug coupons can also lead to uncertainty about a patient’s out-of-pocket costs from month-to-month, since pharmaceutical companies can change their coupon programs and patient eligibility rules for those programs at any time,” wrote the Senators in laying out the problem. “We are concerned that these coupons can enable drug manufacturers and pharmacy benefit managers to maintain high list prices and drive up costs for all patients through higher insurance premiums.” Senator Hassan is working to lower prescription drug costs for Americans. Earlier this year, two of Senator Hassan’s bipartisan measures to lower prescription drug costs passed into law. The Increasing Transparency in Generic Drug Applications Act will speed the approval of generic drugs by ending the lengthy guessing game that manufacturers currently go through with the FDA, enabling generic drugs to get to market sooner, lowering prices for consumers, and saving taxpayer dollars. The Patients Before Middlemen (PBM) Act helps stop pharmacy benefit managers from driving up prescription drug pricing for seniors. Last month, Senator Hassan successfully forced a big pharmaceutical company to abandon its monopoly and egregious price hike strategy to allow a lower-cost generic inhaler for children to enter the market. Click here or see below for full text of the letter to GAO Acting Comptroller Orice Williams Brown: Dear Acting Comptroller General Brown, We write to request that the Government Accountability Office (GAO) conduct a review of manufacturer prescription drug coupons and their impact on drug utilization and the commercial insurance market. Pharmaceutical companies often offer coupons to privately insured patients in order to provide discounts on brand-name drugs even when lower-cost generic alternatives are available. While these coupons often lower or eliminate the patient’s copays in the short-term, in the long-term they could lead to the patient unnecessarily paying more for the brand-name drug. Brand-name drug coupons can also lead to uncertainty about a patient’s out-of-pocket costs from month-to-month, since pharmaceutical companies can change their coupon programs and patient eligibility rules for those programs at any time. We are concerned that these coupons can enable drug manufacturers and pharmacy benefit managers to maintain high list prices and drive up costs for all patients through higher insurance premiums. Drug companies are often able to keep their drug prices outrageously high by setting their own list prices, and then offering copay coupons in order to help some patients afford those high prices. Companies also use drug coupons to increase drug sales for a particular brand-name drug and to steer patients away from lower-cost generics. In fact, pharmaceutical companies earn as much as $4 more in drug sales for every $1 that they spend on prescription drug coupons. Manufacturers are banned from offering these coupons to patients who are covered by Medicare and Medicaid under anti-kickback laws, due to the fact that the coupons encourage doctors to prescribe more expensive drugs under public payers when cheaper versions are available. One reason why patients may use manufacturer prescription drug coupons is because it is difficult for the patient to determine which prescription drug option will be most affordable. Many patients do not know what they are expected to pay for a drug when they go to the pharmacy counter. One way that patients can get accurate and clinically appropriate information about their most affordable medication option is through an online real-time benefit tool, which shows providers and pharmacists real-time drug cost information, coverage information, and alternative medication options within electronic health record systems. The Consolidated Appropriations Act of 2021 required Medicare Part D plans to increase the use of these real-time benefit tools, and we seek information on how these tools are being used in private insurance plans as well as Medicare Part D. To better understand the impact of prescription drug coupons and the availability of real-time benefit tools in the commercial insurance market, we request that GAO provide responses to the following questions: 1. Describe, to the extent that reliable data are available, the availability and characteristics of manufacturer prescription drug coupons for the highest expenditure prescription drugs in the commercial market. Examples of such characteristics could include whether the drug is single source or has generic equivalent or a biosimilar, whether the drug has a therapeutic substitute, the dollar value of the coupon, who is eligible to use the coupon, and the terms and conditions for the coupon. 2. Describe, based on evidence from published studies, how manufacturer prescription drug coupons can affect the use of a drug. 3. Describe how plan sponsors in the commercial market have responded to the use of manufacturer prescription drug coupons for the highest expenditure prescription drugs, including how coupons are considered in benefit design decisions and patient premium and cost-sharing calculations. 4. Describe the extent to which prescribers, patients, and pharmacists are able to access to electronic real-time benefit tools in the commercial health insurance market. Thank you for your prompt attention to this request.

Senator Hassan Statement on Israel Arms Sales Vote... | U.S. Senator Maggie Hassan of New Hampshire

Position: Senator Hassan supports the U.S.-Israel alliance but opposes the current weapons sales to Israel, citing the lack of congressional authorization for the war, the absence of a clear rationale and strategy, and concerns about Prime Minister Netanyahu's regional expansion and settlement policies.

WASHINGTON – U.S. Senator Maggie Hassan (D-NH) released the following statement today after voting on weapons sales to Israel: "Throughout my time in public service, I have supported the unshakable alliance between the United States and Israel, built on our shared democratic values. In recent years, the Israeli people have suffered unspeakable atrocities, most notably the horrific October 7 attacks by Hamas and the slaughter of 1,200 people, and our support is vital to preserving the only Jewish state in the world. That is why I will always work to ensure that the United States remains Israel’s strongest and most dependable ally. “I evaluate all sales of military equipment on a case-by-case basis. In this case, my assessment is informed by President Trump’s and Prime Minister Netanyahu’s reckless decision to go to war, a war that has cost American servicemembers their lives, undermined our national security, and increased costs beyond the breaking point for many American families. “To date, the President has failed to provide the American people with a consistent, let alone legitimate, rationale for going to war. He has also failed to meet his constitutional obligation to make his case for war to Congress and get approval for it from the people’s representatives. In the absence of a clear rationale and strategy for this war and given the President’s failure to obtain authorization to conduct this war from the American people, I have serious questions about any supplemental expenditures for this war, let alone additional sales of weapons for the same war to Israel. “The world will be better off if we can achieve a two-state solution that allows Israel to live in peace with the Palestinian people and its other neighbors. But Prime Minister Netanyahu has undermined that goal by expanding his war in the region and through other actions such as support for unlawful settlements in the West Bank. “Israel is one of our closest allies and always will be. But supporting a friend can sometimes mean speaking up about hard truths. I have and will always support Israel’s right to exist and defend itself, but at this time, I do not support these sales to Israel.”

Senator Hassan Meets with Law Enforcement Official... | U.S. Senator Maggie Hassan of New Hampshire

Position: Senator Hassan supports strengthened border security measures to counter drug trafficking and terrorism, while expressing concern about ICE enforcement tactics under the Trump Administration and advocating for orderly immigration practices consistent with American values.

Hassan Hears About Threats to National Security, Discusses Olympic Security; Inspects Conditions at ICE Detention Facility WASHINGTON – U.S. Senator Maggie Hassan (D-NH), a senior member of the Senate Homeland Security Committee, last week met with federal law enforcement agents in California and discussed efforts to counter drug trafficking, terrorism, and other national security threats at the Southern border. During the trip, which comes amid concerns about the lawlessness of the Trump Administration’s immigration enforcement efforts, Senator Hassan also inspected conditions at an ICE detention facility. “We need to strengthen security at our Southern border to stop drug trafficking and ensure that we have an immigration system that is orderly and consistent with our values,” said Senator Hassan. “I was grateful to meet with federal law enforcement officials who are working to secure our southern border and intercept illegal drugs. I am also deeply concerned by the tactics used by ICE since President Trump took office, which is why I conducted oversight of ICE at a detention facility as the Senate continues to discuss reining in the agency’s lawlessness.” Senator Hassan met in San Diego with federal law enforcement officers from the Drug Enforcement Agency, the Federal Bureau of Investigation, and the Bureau of Alcohol, Tobacco, Firearms, and Explosives to discuss the current state of cross-border crime and threats that the country faces. Later, the Senator visited the Otay Mesa ICE Detention Facility in San Diego, which has been the subject of scrutiny for reports of abuse and neglect of detainees. During the trip, Senator Hassan also visited the Port of Los Angeles to discuss port safety and security with the Chief of the Los Angeles Port Police, with a focus on efforts to intercept illegal drugs and prevent terrorism. The Senator also met with officials from the Los Angeles 2028 Olympics Organizing Committee to discuss how they are preparing for security at the 2028 Summer Olympics and Paralympics. Senator Hassan’s visit is part of her efforts to strengthen border security. Senator Hassan leads bipartisan legislation to increase inspections of traffic crossing the border from the U.S. to Mexico to stop the flow of illicit firearms and money that fuels drug cartels. She also has introduced bipartisan legislation that has previously advanced through the Senate Homeland Security Committee that would allow U.S. and Canadian personnel to jointly patrol both sides of the northern border on aircraft, helping to more effectively combat drug smuggling and other illegal cross-border activities. Additionally, last year, the DETECT Fentanyl and Xylazine Act, a bipartisan bill backed by Senator Hassan that empowers law enforcement with research, information, and technologies to find and eliminate illegal deadly drugs, was signed into law.

Senator Hassan Invites New Hampshire Mobile Home P... | U.S. Senator Maggie Hassan of New Hampshire

WASHINGTON – U.S. Senator Maggie Hassan (D-NH), Ranking Member of the Joint Economic Committee, today launched a community survey to learn more about the experiences of Granite Staters living in mobile home communities. In recent years, as big corporations have bought up more of these communities, reports of exploitative rent increases and neglected facilities have surged. Last December, Senator Hassan launched an investigation into the largest corporate owners of American mobile home parks, pressing the companies for answers on how their business practices affect residents in New England. Responses to the community survey will inform Senator Hassan’s investigation and efforts to improve Granite Staters’ access to safe, affordable housing. Survey responses will remain confidential unless residents provide permission to share their names. “The residents of New Hampshire’s mobile home communities deserve affordable rent, safe living conditions, and the ability to protect themselves from mistreatment,” said Senator Hassan. “If you live in one of these communities, I would love to hear from you. By completing the survey, you can share your experiences and support our work to protect Granite Staters from being pushed out of their own homes due to rising rents.” Click here or on the banner at the top of Hassan.Senate.Gov to take the New Hampshire community survey on the conditions in mobile home communities.

Senator Hassan Statement on Senate Vote to Fund TS... | U.S. Senator Maggie Hassan of New Hampshire

Position: Senator Hassan supports funding for TSA, FEMA, and DHS agencies and calls for reforms to ICE operations, citing concerns about conduct by federal immigration agents and the need for ICE to meet standards comparable to local law enforcement.

WASHINGTON — U.S. Senator Maggie Hassan (D-NH) released the following statement after this morning’s vote to fund the Transportation Security Agency (TSA), the Federal Emergency Management Agency (FEMA), and other Department of Homeland Security agencies while continuing to press for common-sense reforms to ICE: “Granite Staters count on their government to work for them and to keep them safe. The chaos at our airports is unacceptable — and so is the conduct of masked federal immigration agents, which resulted in the killings of Renee Good and Alex Pretti in Minneapolis. “For several weeks, I’ve supported efforts to fund TSA, FEMA, the Coast Guard, and other agencies at the Department of Homeland Security while Congress negotiates reforms to ICE — but President Trump refused. Thankfully, the President finally relented, and Granite Staters can breathe a sigh of relief now that the Senate passed this funding on a bipartisan basis. “There is still significant work ahead. People in New Hampshire and across the country are demanding common-sense reforms to ICE, which would bring the agency in line with standards that local law enforcement officers are proud to meet every day. All Americans must continue to press for these reforms because the safety of our communities depends on it.”

Senator Hassan Secures Commitments from FBI & Depa... | U.S. Senator Maggie Hassan of New Hampshire

WASHINGTON – U.S. Senator Maggie Hassan (D-NH), Ranking Member of the Joint Economic Committee, led a bipartisan Congressional hearing yesterday on ways to strengthen efforts to combat scams. The hearing included testimony from top leaders at the U.S. Department of Justice and the FBI, as well as representatives from AARP, Aspen Institute, and other entities. The hearing is part of Senator Hassan’s ongoing comprehensive push to combat scams. Throughout the hearing, Senator Hassan pressed federal officials on the fragmented approach to scams – which also leads to confusion among the general public about where to report scams. She secured several commitments from the federal agency leaders to help improve coordination with state and local law enforcement, and to make it easier for people to report scams and get help. “One of the great frustrations I hear on the ground is there are any number of places to report [scams],” said Senator Hassan at the hearing. “I’m working with Senator Rick Scott on a bipartisan bill that…would create a central secure website for Americans to report scams and get assistance, as well as a comprehensive federal strategy to prevent scams...and hold scammers accountable to the fullest extent of the law.” Senator Hassan secured commitments from Gregory Heeb, Deputy Assistant Director of the Criminal Division at the FBI and Lois Greisman, the Associate Director of the Division of Marketing Practices at the Federal Trade Commission, to work with her office to simplify the scam reporting process for all Americans. “Senator, yes, absolutely. It is confusing,” responded Mr. Heeb. Ms. Greisman added, “Yes, of course, we commit to making it easier for consumers to report.” Senator Hassan also highlighted the recent experience of a constituent from Derry and the difficulty that he has encountered in getting help. After his mother was scammed out of $80,000 by fraudsters who impersonated the FBI over the phone, he compiled case details and evidence for law enforcement, including the FBI, and his mother’s bank. “But he’s still struggling to get help. He’s also unsure whether federal authorities have taken any action,” Senator Hassan said. Later in the hearing, Senator Hassan secured a commitment from the FBI to help this constituent, asking, “Can you commit to working with my office and reaching out to this constituent this week?” Mr. Heeb responded, “Yes, we can, Senator...I’ll take care of that.” In addition, Senator Hassan raised concerns about the lack of coordination between state and local law enforcement and federal efforts, including the Scam Center Strike Force, a multi-agency task force investigating scam activity in Southeast Asia. “State and local law enforcement…are often the first point of contact when victims report a scam. Yet, New Hampshire law enforcement officers we reached out to recently weren’t even aware that the [Scam Center] Strike Force exists,” said Senator Hassan. “As important as the work you’re doing to go after the overall criminal organizations, we have to have coordination on the state and local level too.” Karen Seifert, Director of the Scam Center Strike Force at the U.S. Attorney’s Office of the District of Columbia, agreed that “absolutely” she will engage further with Senator Hassan’s office on this, while acknowledging that “we haven’t had that pathway so far.” During the hearing’s second panel of witnesses, Senator Hassan talked with experts from AARP, the Aspen Institute, and the Government Accountability Office about her push to strengthen federal scams coordination and develop a centralized portal for Americans to report scams – and how that might help address the challenges that they have seen Americans face. Senator Hassan also discussed with the experts the importance of facilitating real-time information sharing between the private and public sectors as an important tool when combatting scams.